iPierian
iPierian develops novel therapies for neurodegenerative diseases.
Business Model:
Revenue: $21.8M
Employees: 51-200
Rankings
Industries / Tags:
Detailed iPierian Information
iPierian was acquired by
Bristol Myers Squibb.
The acquisition happend on 2014-04-29.
Details of the transaction were not public
Acquirer
Geographic Data
Address: 951 Gateway Blvd
City: South San Francisco
State: CA
Zip: 94080
Country: US
Financial Info
Stage:
series unknown
Raised Last:
$0
Raised Total:$58M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
iPierian develops novel therapies for neurodegenerative diseases.
Contact Phone:
+16508724700
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 7/2009 | Series A | $6.5M | 11/2010 | Series B | 8 | $29M |
SR One Biogen Idec Highland Capital Partners ATEL Ventures MPM Capital GV GV Mitsubishi UFJ Capital Kleiner Perkins SR One Biogen Idec Highland Capital Partners ATEL Ventures MPM Capital GV GV |
9/2013 | Venture Round | 3 | $30M |
Kleiner Perkins MPM Capital SR One Kleiner Perkins MPM Capital SR One Kleiner Perkins MPM Capital SR One Kleiner Perkins MPM Capital SR One |
10/2009 | Grant | $3.7M | 9/2010 | Series C | $28M |
Google Ventures |
1/2017 | Venture Round | 1 | - |
Mission BioCapital Mission BioCapital |
7/2009 | Venture Round | 3 | $11.5M |
MPM Capital Kleiner Perkins Highland Capital Partners |
1/2017 | Venture Round | 1 | - |
Mission BioCapital Mission BioCapital |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 7/2009 | iZumi Bio |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
